

**Revised Draft Agenda**  
**Biocides Working Group Meeting IV-2021**  
**16 – 26 November 2021**

**WG-IV-2021 meetings are held as virtual meetings via WebEx**

The time is indicated in Helsinki time.

Tuesday 16 Nov	10:00-17:00	APCP WG
Wednesday 17 Nov	10:00-17:00	APCP WG
Thursday 18 Nov	10:00-17:00	APCP WG
Wednesday 24 Nov	10:00-18:00	TOX WG
Thursday 25 Nov	10:30-18:00	TOX WG
Friday 26 Nov	10:00-17:00	TOX WG
Wednesday 17 Nov	10:30-18:00	EFF WG
Friday 19 Nov	10:00-16:30	EFF WG
Tuesday 23 Nov	10:30-13:30	EFF WG
Thursday 18 Nov	10:00-18:00	AHEE-6
Monday 22 Nov	10:00-17:00	ENV WG
Tuesday 23 Nov	10:00-17:00	ENV WG
Thursday 25 Nov	10:00-13:00	ENV WG
	14:00-18:00	AHEE-6

<b>Analytical methods and physico-chemical properties Working Group</b>  <b>Chair: Bernhard Krebs</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement on the minutes of WG III 2021</b>		<i>For agreement</i>
<b>Item 6 – Outcome of e-consultations and follow-ups (closed session)</b>		
<b>Item 7 - Discussion on Active Substances</b>		<b>eCA</b>
<b>7.1</b>	<b>Methylene dithiocyanate</b> PT 12 Meeting document: <i>WG IV 2021_APCP_7-1</i>  <i>For agreement</i>	FR
<b>7.2</b>	<b>(13Z)-Hexadec-13-en-11-yn-1-yl acetate</b> PT 19 Meeting document: <i>WG IV 2021_APCP_7-2</i>  <i>For agreement</i>	FR
<b>7.3</b>	<b>Propiconazole</b> PT 08 Meeting document: <i>WG IV 2021_APCP_7-3</i>  <i>For agreement</i>	FI
<b>Item 8 - Discussions on Union Authorisations</b>		<b>eCA</b>
<b>8.1</b>	<b>UA for a product family containing Propan-1-ol</b> PT 01 (BC-RS050191-24) Meeting document: <i>WG IV 2021_APCP_8-1</i>  <i>For agreement</i>	SE
<b>8.2</b>	<b>UA for a product family containing Propan-2-ol</b> PT 02, 04 (BC-HN024859-20) Meeting document: <i>WG IV 2021_APCP_8-2</i>  <i>For agreement</i>	NL

8.3	<b>UA for a product family containing L-(+)-lactic acid</b> PT 02 (BC-HK051319-37) Meeting document: <i>WG IV 2021_APCP_8-3</i> <i>For agreement</i>	FR
8.4	<b>UA for a product family containing Active chlorine released from sodium hypochlorite</b> PT 02, 04 (BC-NB046342-57) Meeting document: <i>WG IV 2021_APCP_8-4</i> <i>For agreement</i>	FR
8.5	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02 (BC-EF047438-44) Meeting document: <i>WG IV 2021_APCP_8-5</i> <i>For agreement</i>	FR
<b>Item 9 – AoB</b>		
9.1	Post-authorisation data	DE

<b>Human Health Working Group</b>		
<b>Chair: Antero Airaksinen</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes from WG-III-2021</b>		<i>For agreement</i>
<b>Item 6 - Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>Methylene dithiocyanate</b> PT 12 Meeting document: <i>WGIV2021_TOX_6-1</i>	FR  <i>For agreement</i>
<b>6.2</b>	<b>(13Z)-Hexadec-13-en-11-yn-1-yl acetate</b> PT 19 Meeting document: <i>WGIV2021_TOX_6-2</i>	FR  <i>For agreement</i>
<b>6.3</b>	<b>Propiconazole</b> PT 8 Meeting document: <i>WGIV2021_TOX_6-3</i>	FI  <i>For agreement</i>
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for a product family containing L-(+)-lactic acid</b> PT 2 (BC-HK051319-37) Meeting document: <i>WGIV2021_TOX_7-1</i>	FR  <i>For agreement</i>
<b>7.2</b>	<b>UA for a product family containing Propan-2-ol</b> PT 2, 4 (BC-HN024859-20) Meeting document: <i>WGIV2021_TOX_7-2</i>	NL  <i>For agreement</i>
<b>7.3</b>	<b>UA for a product family containing Propan-1-ol</b> PT 1 (BC-RS050191-24) Meeting document: <i>WGIV2021_TOX_7-3</i>	SE  <i>For agreement</i>

7.4	<b>UA for a product family containing Active chlorine released from sodium hypochlorite</b> PT 2 (BC-EF047438-44) Meeting document: <i>WGIV2021_TOX_7-4</i> <i>For agreement</i>	FR
7.5	<b>UA for a product family containing Active chlorine released from sodium hypochlorite</b> PT 2, 4 (BC-NB046342-57) Meeting document: <i>WGIV2021_TOX_7-5</i> <i>For agreement</i>	FR
<b>Item 8 - Technical and guidance related issues</b>		<b>Presenter</b>
8.1	<b>Update on guidance development</b> Meeting document: <i>WGIV2021_TOX_8-1</i> <i>For discussion</i>	SECR
<b>Item 9 – AOB</b>		<b>Presenter</b>
9.1	<b>Other information &amp; lessons learned</b> Meeting document: <i>WGIV2021_TOX_9-1</i> <i>For discussion</i>	SECR

<b>AHEE-6</b> <b>Chair: Heike Schimmelpfennig</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 - Discussion of technical and guidance related topics</b>		<b>eCA</b>
<b>4.1</b>	<b>PT 11: Step-by-step guidance to calculate PECsoil</b> Meeting document: <i>AHEE-6_AP4-1</i>  <i>For agreement</i>	NL
<b>4.2</b>	<b>PT 3/PT 18: Simplification of degradation in manure calculations following EMA approach</b> Meeting document: <i>AHEE-6_AP4-2</i>  <i>For discussion</i>	DE
<b>4.3</b>	<b>PT 18: Revised Addendum</b> Meeting document: <i>AHEE-6_AP4-3</i>  <i>For agreement</i>	NL
<b>4.4</b>	<b>PT 18: Development/formalisation of space spray (overspray) application scenario</b> Meeting document: <i>AHEE-6_AP4-4</i>  <i>For discussion</i>	ECHA
<b>4.5</b>	<b>PT 19: Follow up emission scenarios for repellent diffuser devices used in residential areas, by fishermen or on campsites</b> Meeting document: <i>AHEE-6_AP4-5</i>  <i>For agreement</i>	ECHA
<b>4.6</b>	<b>PT 21: Comparison of modelling outcomes between MAMPEC versions 3.1.0.3 and 3.1.0.5 for selected EU freshwater marinas</b> Meeting document: <i>AHEE-6_AP4-6</i>  <i>For information</i>	NL
<b>4.7</b>	<b>Calculation of PEC<sub>sediment</sub> in a ditch: explanation and comparison of three different methods (triggered by Chrysanthemum discussions)</b> Meeting document: <i>AHEE-6_AP4-7</i>  <i>For information</i>	NL

4.8	<p><b>Clarification on which rates (k) and time windows (t) to use in the TWA-factor for PEC and PNEC</b></p> <p>Meeting document: <i>AHEE-6_AP4-8</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SE
4.9	<p><b>New developments in FOCUS models – relevance for biocides assessment</b></p> <p>Meeting document: <i>AHEE-6_AP4-9</i></p> <p style="text-align: right;"><i>For information/discussion</i></p>	ECHA

<b>Environment Working Group</b> <b>Chair: Heike Schimmelpfennig</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes of WG-III-2021</b>		<i>For agreement</i>
<b>Item 6 - Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>Methylene dithiocyanate</b> PT 12 Meeting document: <i>WGIV2021_ENV_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>6.2</b>	<b>(13Z)-Hexadec-13-en-11-yn-1-yl acetate</b> PT 19 Meeting document: <i>WGIV2021_ENV_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>6.3</b>	<b>Propiconazole</b> PT 8 Meeting document: <i>WGIV2021_ENV_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	FI
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for a product family containing L-(+)-lactic acid</b> PT 02 (BC-HK051319-37) Meeting document: <i>WGIV2021_ENV_7-1</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>7.2</b>	<b>UA for a product family containing Propan-2-ol</b> PT 02, 04 (BC-HN024859-20) Meeting document: <i>WGIV2021_ENV_7-2</i> <div style="text-align: right;"><i>For agreement</i></div>	NL



7.3	<b>UA for a product family containing Active chlorine released from sodium hypochlorite</b> PT 02 (BC-EF047438-44) Meeting document: <i>WGIV2021_ENV_7-3</i> <i>For agreement</i>	FR
7.4	<b>UA for a product family containing Active chlorine released from sodium hypochlorite</b> PT 02, 04 (BC-NB046342-57) Meeting document: <i>WGIV2021_ENV_7-4</i> <i>For agreement</i>	FR
7.5	<b>UA for a product family containing Propan-1-ol</b> PT 01 (BC-RS050191-24) Meeting document: <i>WGIV2021_ENV_7-5</i> <i>For agreement</i>	SE
<b>Item 8 – AOB</b>		
8.1	<b>Other information &amp; lessons learned</b> SECR to inform <i>For information</i>	SECR

<b>Efficacy Working Group</b>		
<b>Chair: Kasia Szymankiewicz</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes from WG-III-2021</b>		<i>For agreement</i>
<b>Item 6 - Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>Methylene dithiocyanate</b> PT 12 Meeting document: <i>WGIV2021_EFF_6-1</i>	FR  <i>For agreement</i>
<b>6.2</b>	<b>(13Z)-Hexadec-13-en-11-yn-1-yl acetate</b> PT 19 Meeting document: <i>WGIV2021_EFF_6-2</i>	FR  <i>For agreement</i>
<b>6.3</b>	<b>Propiconazole</b> PT 8 Meeting document: <i>WGIV2021_EFF_6-3</i>	FI  <i>For agreement</i>
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for a product family containing L-(+)-lactic acid</b> PT 02 (BC-HK051319-37) Meeting document: <i>WGIV2021_EFF_7-1</i>	FR  <i>For agreement</i>
<b>7.2</b>	<b>UA for a product family containing Propan-2-ol</b> PT 02, 04 (BC-HN024859-20) Meeting document: <i>WGIV2021_EFF_7-2</i>	NL  <i>For agreement</i>

7.3	<p><b>UA for a product family containing Active chlorine released from sodium hypochlorite</b>  PT 02 (BC-EF047438-44)  Meeting document: <i>WGIV2021_EFF_7-3</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
7.4	<p><b>UA for a product family containing Active chlorine released from sodium hypochlorite</b>  PT 02, 04 (BC-NB046342-57)  Meeting document: <i>WGIV2021_EFF_7-4</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
7.5	<p><b>UA for a product family containing Propan-1-ol</b>  PT 01 (BC-RS050191-24)  Meeting document: <i>WGIV2021_EFF_7-5</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SE
<b>Item 8 - Technical and guidance related issues</b>		
8.1	<p><b>PT12 draft guidance – oilfield part</b>  Meeting document: <i>WGIV2021_EFF_8-1</i></p> <p style="text-align: right;"><i>For discussion</i></p>	FR
8.2	<p><b>TAB proposals:</b></p> <ul style="list-style-type: none"> <li>• <b>Disinfectants testing at elevated temperatures</b>  Meeting document: <i>WGIV2021_EFF_8-2a</i></li> <li>• <b>PT14 products with lowered AS concentration</b>  Meeting document: <i>WGIV2021_EFF_8-2b</i></li> <li>• <b>PT1-5 Use concentration and contact time</b>  Meeting document: <i>WGIV2021_EFF_8-2c</i></li> </ul> <p style="text-align: right;"><i>For discussion</i></p>	DE/NL
<b>Item 9 – AOB</b>		
9.1	<p><b>Other information</b>  Meeting document: <i>WGIV2021_EFF_9-1</i></p> <p style="text-align: right;"><i>For information</i></p>	ECHA